久久精品亚洲夜色国产av,亚洲AV无码成人精品区,亚洲日本乱码一区二区产线一,国产成人a福利在线观看,在线影音先锋制服丝袜中文字幕

患者招募

關(guān)于我們

董事長(cháng)致辭公司簡(jiǎn)介管理團隊

創(chuàng )新與藥物

研究領(lǐng)域產(chǎn)品管線(xiàn)

公司新聞醫學(xué)進(jìn)展發(fā)表文章

聯(lián)系我們

聯(lián)系我們

發(fā)表文章

公司新聞醫學(xué)進(jìn)展發(fā)表文章

A Novel Extended half-life factor VIII Fc fusion protein FRSW107 for severe hemophilia A: A multicentre, open-label, single-arm, phase 3 study and its open-label extension

An Open-label,Dose-Escalation, Multicenter Phase I Study to Evaluate the Safety, Immunogenicity, and Pharmacokinetics/pharmacodynamics（PK/PD）of Single Dose SS109 in Hemophilia A/B patients with Inhibitor

The in vitro and in vivo hemostatic efficacies of a novel FVIIIamimetic bispecific antibody, SS315, for the treatment of Hemophilia A.

Pharmacokinetics, Safety and Preliminary Efficacy of Multiple Doses of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW117) in Previously Treated Adult and Adolescent Subjects with Severe Hemophilia a: Results from an Open-

A Phase 1 Study to Evaluate the Pharmacokinetics and Safety of a PEGylated-Recombinant Human Coagulation Factor VIII-Fc Fusion Protein in Patients With Severe Hemophilia A

A Phase 1 Study to Evaluate the PK, Safety and Tolerability of a PEGylated-Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW117) with Extended Half-Life in Patients With Severe Hemophilia A

Pharmacokinetics, Efficacy and Safety Evaluation of FRSW107 in Previously Treated Hemophilia a Patients: A Multicentre, Open-Label, Non-Randomized Phase III Study

共7條
1

版權所有: 江蘇晟斯生物制藥有限公司蘇ICP備2022048559號-2 ghs 蘇公網(wǎng)安備32060002000102號

久久精品亚洲夜色国产av,亚洲AV无码成人精品区,亚洲日本乱码一区二区产线一,国产成人a福利在线观看,在线影音先锋制服丝袜中文字幕